Bioz, Inc. to Present at GBSI BioPolicy Summit 2017

PALO ALTO, Calif. - October 13, 2017

Bioz, Inc., developers of the world's first and most comprehensive search engine for life science experimentation, today announced their co-founder and CEO Daniel Levitt, will speak at the annual Global Biological Standards Institute BioPolicy Summit, taking place on October 16, 2017.

Levitt will deliver a talk during the "Experiment Design" session titled "Bioz Stars - Objective Data-Driven Reagent & Tool Ratings." He will provide an overview of how advanced natural language processing (NLP), machine learning and artificial intelligence (AI) technologies can transform the way the life science industry evaluates lab products, such as reagents and equipment, and how that ultimately accelerates the pace of drug discovery.

By harnessing the power of AI, Bioz provides researchers with an unprecedented amount of summarized scientific experimentation knowledge right at their fingertips, ultimately accelerating drug discovery and improving the rate of success in finding cures for diseases. Since the company emerged from stealth in July 2016, Bioz has surpassed one million users in 196 countries.

For those interested in attending Levitt's presentation, please refer to the following information:

• What: Bioz-Stars "Objective Data-Driven Reagent & Tool Ratings" talk during the "Experiment Design" session

• Who: Daniel Levitt, co-founder and CEO of Bioz, Inc.

• When: Monday, October 16 at 11:50 a.m. PT

• Where: Mission Bay Conference Center at UCSF

To schedule a meeting with Bioz at GBSI BioPolicy Summit, please reach out to

Suggested Tweet: @BiozPage's Daniel Levitt to speak on objective #DataDriven reagent & tool ratings at @GBSIorg BioPolicy Summit:

About Bioz, Inc.

Bioz, Inc. offers the world's first search engine for life science experimentation. The patent-pending software platform combines the work of scientists with advanced artificial intelligence (AI), focused on natural language processing (NLP) and machine learning (ML) technology to help life scientists in academia and biopharma make faster and smarter experimentation decisions, ultimately speeding up drug discovery and increasing the rate of success in finding cures for diseases. Founded in 2013 by Stanford research scientist, Karin Lachmi, Ph.D., and CEO Daniel Levitt, Bioz is a Stanford-StartX accelerator company. Over one million researchers from 10,000 different academic institutions and biopharma companies in 196 countries use Bioz. Try Bioz at

Media Contact:

Victoria Khamsombath
SHIFT Communications